Advertisement

5-Hydroxytryptamine transport systems

  • David Graham
  • Salomon Z. Langer
Chapter
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)

Abstract

Studies on the uptake of radioactively-labelled 5-hydroxytryptamine (5-HT) have revealed the accumulation of this biogenic amine in a number of different tissues. In many instances this accumulation of 5-HT represents a temperature-dependent, saturable uptake process which can be inhibited by metabolic inhibitors and by certain selectively-acting compounds. These observations indicate the presence of specific carrier or transport systems involved in the active transport of 5-HT into specific tissue elements.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Maron R, Kanner B, Schuldiner S (1979): The role of a transmembrane pH gradient in 5-hydroxytryptamine uptake by synaptic vesicles from rat brain. FEBS Letts 98: 237–240.CrossRefGoogle Scholar
  2. 2.
    Wilkins JA, Greenawalt JW, Huang L (1978): Transport of 5-hydroxytryptamine by dense granules from porcine platelets. J Biol Chem253: 6260–6265.PubMedGoogle Scholar
  3. 3.
    Rudnick G, Fishkes H, Nelson PJ, Schuldiner S (1980): Evidence for two distinct serotonin transport systems in platelets. J Biol Chem255: 3638–3641.PubMedGoogle Scholar
  4. 4.
    Pletscher A, Da Prada M, Berneis KH, Tranzer JP (1971): New aspects on the storage of 5-hydroxytryptamine in blood platelets. Experientia27: 993–1120.PubMedCrossRefGoogle Scholar
  5. 5.
    Scherman D (1986): Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem47: 331–339.PubMedCrossRefGoogle Scholar
  6. 6.
    Darchen F, Scherman D, Laduron PM, Henry J-P (1988): Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol33: 672–677.PubMedGoogle Scholar
  7. 7.
    Kanner BI (1983): Bioenergetics of neurotransmitter transport. Biochim Biophys Acta726: 293–316.PubMedCrossRefGoogle Scholar
  8. 8.
    Njus D, Radda GK (1978): Bioenergetic processes in chromaffin granules: a new perspective on some old problems. Biochim Biophys Acta463: 219–244.PubMedCrossRefGoogle Scholar
  9. 9.
    Angelides KJ (1980): Transport of catecholamines by native and reconstituted rat heart synaptic vesicles. J Neuro chem35: 949–962.Google Scholar
  10. 10.
    Greene LA, Rein G (1977): Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res129: 247–263.PubMedCrossRefGoogle Scholar
  11. 11.
    Da Prada M, Obrist R, Pletscher A (1975): Discrimination of monoamine uptake by membranes of adrenal chromaffin granules. Br J Pharmacol53: 257–265.PubMedCrossRefGoogle Scholar
  12. 12.
    Sneddon JM (1973): Blood platelets as a model for monoamine-containing neurones. Prog Neurobiol1: 151–198.PubMedCrossRefGoogle Scholar
  13. 13.
    Stahl SM, Meltzer HY (1978): A kinetic and pharmacological analysis of 5-hydroxytrypt- amine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons.J Pharmacol Exp Ther205: 118–132.Google Scholar
  14. 14.
    Bogdanski DF, Tissari AH, Brodie BB (1970): Mechanism of transport and storage of biogenic amines. III. Effects of sodium and potassium on kinetics of 5-hydroxytryptamine and noradrenaline transport by rabbit synaptosomes. Biochim Biophys Acta219: 189–199.PubMedCrossRefGoogle Scholar
  15. 15.
    Shaskan EG, Snyder SH (1970): Kinetics of serotonin accumulation into slices from rat brain. Relationship to catecholamine uptake. J Pharmacol Exp Ther175: 404–418.PubMedGoogle Scholar
  16. 16.
    Gershon MD, Jonakait GM (1979): Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurones: effects of fluoxetine (Lilly 110140) and chlorimipramine. Br J Pharmacol66: 7–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Suddith RL, Hutchinson HT, Haber B (1978): Uptake of biogenic amines by glial cells in culture. 1. A neuronal-like transport of serotonin. Life Sci22: 2179–2188.PubMedCrossRefGoogle Scholar
  18. 18.
    Kimelberg HK (1986): Occurrence and functional significance of serotonin and catecholamine uptake by astrocytes. Biochem Pharmacol35: 2273–2281.PubMedCrossRefGoogle Scholar
  19. 19.
    Gripenberg J (1976): Inhibition by reserpine, guanethidine and imipramine of the uptake of 5-hydroxytryptamine by rat peritoneal mast cells in vivo. Acta Physiol Scand 96: 407–416.PubMedCrossRefGoogle Scholar
  20. 20.
    Bosin TR, Lahr PD (1981): Mechanisms influencing the disposition of serotonin in mouse lung. Biochem Pharmacol30: 3187–3193.PubMedCrossRefGoogle Scholar
  21. 21.
    Raisman R, Langer SZ (1983): Specific high affinity [3H]imipramine binding sites in rat lung are related with a non-neuronal uptake site for serotonin. Eur J Pharmacol94: 345–348.PubMedCrossRefGoogle Scholar
  22. 22.
    Stahl SM (1977): The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiat 34: 509–516.PubMedCrossRefGoogle Scholar
  23. 23.
    Segonzac A, Tateishi T, Langer SZ (1984): Saturable uptake of [3H]tryptamine in rabbit platelets is inhibited by 5-hydroxytryptamine uptake blockers. Naunyn-Schmiedeberg’s Arch Pharmacol328: 33–37.CrossRefGoogle Scholar
  24. 24.
    Ross SB, Ask AL (1980): Structural requirements for uptake into serotonergic neurons. Acta Pharmacol Toxicol46: 270–277.CrossRefGoogle Scholar
  25. 25.
    Da Prada M, Cesura AM, Launay JM, Richards JG (1988): Platelets as a model for neurones. Experientia44: 115–126.PubMedCrossRefGoogle Scholar
  26. 26.
    Thoa NB, Ecclestone D, Axelrod J (1969): The accumulation of 14C-serotonin in the guinea-pig vas deferens. J Pharmacol Exp Ther169: 68–73.PubMedGoogle Scholar
  27. 27.
    Lindström P, Sehlin J, Täljedal I-B (1980): Characteristics of 5-hydroxytryptamine transport in pancreatic islets. Br J Pharmacol68: 773–778.PubMedCrossRefGoogle Scholar
  28. 28.
    Verbeuren TJ, Jordaens FH, Herman AG (1983): Accumulation and release of [3H]5- hydroxytryptamine in saphenous veins and cerebral arteries of the dog. J Pharmacol Exp Ther226: 579–588.PubMedGoogle Scholar
  29. 29.
    Ducis I, Di Stefano V (1980): Characterization of serotonin uptake in isolated pinealocyte suspensions. Mol Pharmacol18: 447–454.PubMedGoogle Scholar
  30. 30.
    Talvenheimo J, Nelson PJ, Rudnick G (1979): Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport. J Biol Chem254: 4631–4635.PubMedGoogle Scholar
  31. 31.
    Nelson PJ, Rudnick G (1982): The role of chloride ion in platelet serotonin transport. J Biol Chem257: 6151–6155.PubMedGoogle Scholar
  32. 32.
    Ross SB, Helder D (1977): Efflux of 5-hydroxytryptamine from synaptosomes of rat cerebral cortex. Acta Physiol Scand99: 27–36.PubMedCrossRefGoogle Scholar
  33. 33.
    Keyes SR, Rudnick G (1982): Coupling of transmembrane proton gradients to platelet serotonin transport. J Biol Chem257: 1172–1176.PubMedGoogle Scholar
  34. 34.
    Jauch P, Läuger P (1986): Electrogenic properties of the sodium-alanine cotransporter in pancreatic acinar cells: II. Comparison with transport models. J Memb Biol94: 117–127.CrossRefGoogle Scholar
  35. 35.
    Jauch P, Läuger P (1988): Kinetics of the Na+/alanine cotransporter in pancreatic acinar cells. Biochim Biophys Acta939: 179–188.PubMedCrossRefGoogle Scholar
  36. 36.
    Hytell J (1982): Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuro-Psychopharmacol & Biol Psychiat6: 277–295.CrossRefGoogle Scholar
  37. 37.
    Haefely W, Schaffner R, Burkard WP, Da Prada M, Kellar HH, Pole P, Richards JG (1978): Ro 11-2465, a potent and selective inhibitor of 5-hydroxytryptamine uptake. 11th C.I.N.P. Congress, Vienna, July abstracts p. 95.Google Scholar
  38. 38.
    Thomas DR, Nelson DR, Johnson AM (1987): Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology93: 193–200.PubMedCrossRefGoogle Scholar
  39. 39.
    Scatton B, Claustre Y, Graham D, Dennis T, Serrano A, Arbilla S, Pimoule C, Schoemaker H, Bigg D, Langer SZ (1988): SL 81.0385: a novel selective and potent serotonin uptake inhibitor. Drug Dev Res12: 29–40.CrossRefGoogle Scholar
  40. 40.
    Le Fur G, Uzan A (1977): Effects of 4-(3-indolyl-alkyl)-piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in rat brain synaptosomes, rat heart and human blood platelets. Biochem Pharmacol26: 497–503.PubMedCrossRefGoogle Scholar
  41. 41.
    Stark P, Fuller RW, Wong DT (1985): The pharmacologic profile of fluoxetine. J Clin Psychiat46: 7–13.Google Scholar
  42. 42.
    Claassen V (1983): Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 15: 349S–355S.CrossRefGoogle Scholar
  43. 43.
    Graham D, Langer SZ (1988): The neuronal sodium-dependent serotonin transporter: studies with [3H]imipramine and [3H]paroxetine, pp. 367–391 in: Osborne NN, Hamon M (eds), Neuronal Serotonin. John Wiley and Sons Ltd.Google Scholar
  44. 44.
    Langer SZ, Moret C, Raisman R, Dubocovich ML, Briley MS (1980): High affinity [3H]imipramine binding in rat hypothalamus is associated with the uptake of serotonin but not norepinephrine. Science210: 1133–1135.PubMedCrossRefGoogle Scholar
  45. 45.
    Langer SZ, Briley M, Raisman R, Henry J-F, Morselli PL (1980): Specific [3H]imipra- mine binding in human platelets: influence of age and sex. Naunyn-Schmiedeberg’s Arch Pharmacol313: 189–194.CrossRefGoogle Scholar
  46. 46.
    Habert E, Graham D, Tahraoui L, Claustre Y, Langer SZ (1985): Characterization of [3H] paroxetine binding to rat cortical membranes. Eur J Pharmacol118: 107–114.PubMedCrossRefGoogle Scholar
  47. 47.
    Segonzac A, Schoemaker H, Langer SZ (1987): Temperature-dependence of drug interaction with the platelet 5-HT transporter: a clue to the imipramine selectivity paradox. J Neurochem48: 331–339.PubMedCrossRefGoogle Scholar
  48. 48.
    Habert E, Graham D, Langer SZ (1986): Solubilization and characterization of the 5-hydroxytryptamine transporter complex from rat cerebral cortical membranes. Eur J Pharmacol122: 197–204.PubMedCrossRefGoogle Scholar
  49. 49.
    Goodwin FK, Post RM (1983): 5-hydroxytryptamine and depression: a model for the interaction of normal variance with pathology. Br J Clin Pharmacol 15: 393S–405S.CrossRefGoogle Scholar
  50. 50.
    Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S (1975): The use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun1: 239–249.PubMedGoogle Scholar
  51. 51.
    Shopsin B, Friedman E, Gershon S (1976): Parachlorophenylalanine reversal of trancypromine effects in depressed patients. Arch Gen Psychiat33: 811–819.PubMedCrossRefGoogle Scholar
  52. 52.
    Stark P, Hardison CD (1985): A review of multi-centered outpatient imipramine and placebo controlled studies of fluoxetine in the treatment of major depressive disorders. J Clin Psychiatry46: 53 - 58.PubMedGoogle Scholar
  53. 53.
    Penfield P, Ward A (1986): Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32: 313 –334.CrossRefGoogle Scholar
  54. 54.
    Anderson J, Bech P, Benjaminsen S et al. (1986): Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology90: 131 - 138.Google Scholar
  55. 55.
    Simpson RJ, Lawton DJ, Watt MH, Tiplady B (1981): Effect of zimelidine, a new antidepressant, on appetite and body weight. Br J Clin Pharmacol11: 96–98.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Smedgegaard J, Christiansen P, Skrumsager B (1981): Treatment of obesity by femoxetine, a selective 5-HT uptake inhibitor. Int J Obesity5: 377–378.Google Scholar
  57. 57.
    Ferguson JM (1986): Fluoxetine induced weight loss in non-depressed overweight humans. Alimentazione Nutrizione Metabolismo7: (2) 19.Google Scholar
  58. 58.
    Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K (1984): Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther35: 373–381.CrossRefGoogle Scholar
  59. 59.
    Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Sanchez-Craig M, Sykora K (1987): The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 41: 266–214.PubMedCrossRefGoogle Scholar
  60. 60.
    Flood JF, Cherkin A (1987): Fluoxetine enhances memory processing in mice. Psychopharmacology93: 36–43.PubMedCrossRefGoogle Scholar
  61. 61.
    Altman HJ, Nordy DA, Ögen SV (1984): Role of serotonin in memory: facilitation by alaproclate and zimelidine. Psychopharmacology84: 496–502.PubMedCrossRefGoogle Scholar
  62. 62.
    Gabizon R, Schuldiner S (1985): The amine transporter from bovine chromaffin granules. J Biol Chem 260: 3001 -3005.PubMedGoogle Scholar
  63. 63.
    De Lean A, Munson PJ, Rodbard D (1978): Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose- response curves. Am J Physiol 235: E97–El02.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • David Graham
  • Salomon Z. Langer

There are no affiliations available

Personalised recommendations